Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Am Heart Assoc ; 6(5)2017 May 08.
Article in English | MEDLINE | ID: mdl-28483776

ABSTRACT

BACKGROUND: Bioprosthetic heart valves (BHVs), fabricated from glutaraldehyde-pretreated bovine pericardium or porcine aortic valves, are widely used for the surgical or interventional treatment of heart valve disease. Reoperation becomes increasingly necessary over time because of BHV dysfunction. METHODS AND RESULTS: Forty-seven explanted BHV aortic valve replacements were retrieved at reoperation for clinically severe BHV dysfunction over the period 2010-2016. Clinical explant analyses of BHV leaflets for calcium (atomic absorption spectroscopy) and oxidized amino acids, per mass spectroscopy, were primary end points. Comorbidities for earlier BHV explant included diabetes mellitus and coronary artery bypass grafting. Mean calcium levels in BHV leaflets were significantly increased compared with unimplanted BHV (P<0.001); however, time to reoperation did not differ comparing calcified and noncalcified BHV. BHV dityrosine, an oxidized amino acid cross-link, was significantly increased in the explants (227.55±33.27 µmol/mol [dityrosine/tyrosine]) but was undetectable in unimplanted leaflets (P<0.001). BHV regional analyses revealed that dityrosine, ranging from 57.5 to 227.8 µmol/mol (dityrosine/tyrosine), was detectable only in the midleaflet samples, indicating the site-specific nature of dityrosine formation. 3-Chlorotyrosine, an oxidized amino acid formed by myeloperoxidase-catalyzed chlorinating oxidants, correlated with BHV calcium content in leaflet explant analyses from coronary artery bypass graft patients (r=0.62, P=0.01) but was not significantly correlated with calcification in non-coronary artery bypass graft explanted BHV. CONCLUSIONS: Both increased BHV leaflet calcium levels and elevated oxidized amino acids were associated with bioprosthesis dysfunction necessitating reoperation; however, BHV calcium levels were not a determinant of implant duration, indicating a potentially important role for oxidized amino acid formation in BHV dysfunction.


Subject(s)
Aortic Valve Insufficiency/etiology , Aortic Valve Stenosis/etiology , Aortic Valve/pathology , Bioprosthesis , Calcinosis/etiology , Calcium/metabolism , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , Heart Valves/surgery , Oxidative Stress , Prosthesis Failure , Adult , Aged , Aged, 80 and over , Aortic Valve/metabolism , Aortic Valve/surgery , Aortic Valve Insufficiency/metabolism , Aortic Valve Insufficiency/pathology , Aortic Valve Insufficiency/surgery , Aortic Valve Stenosis/metabolism , Aortic Valve Stenosis/pathology , Aortic Valve Stenosis/surgery , Calcinosis/metabolism , Calcinosis/pathology , Calcinosis/surgery , Comorbidity , Depsipeptides/metabolism , Device Removal , Disease Progression , Female , Heart Valve Prosthesis Implantation/adverse effects , Heart Valves/metabolism , Heart Valves/pathology , Humans , Male , Mass Spectrometry , Middle Aged , Prosthesis Design , Registries , Risk Factors , Spectrophotometry, Atomic , Time Factors , Treatment Outcome , Tyrosine/analogs & derivatives , Tyrosine/metabolism , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL